我的购物车

PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair

用户评价
货号-规格
价格
Qty.
合计0件 产品金额0
0
加入购物车

产品详情

  • 组分(Materials Provided)

    ID
    Components
    Size
    A006-214
    Human LDL R
    35μg
    A007-214
    Biotinylated Human PCSK9
    10μg
    A003-214
    Streptavidin-HRP
    10μg
    PC9-NA003
    Anti-PCSK9 Neutralizing Antibody
    40μg
    480tests

  • 产品概述(Product Overview)

    PCSK9 [Biotinylated] : LDL R Inhibitor Screening ELISA Assay Pair is based on a competition-ELISA method, is used to screening for inhibitors of human PCSK9 binding to human LDL R. The kit is designed to provide a reliable solution for the screening of antibodies and small molecule inhibitors in the early stages, as well as QC release, to help researchers quickly screen and validate drugs, effectively improving research and development efficiency. It can also be used as a universal detection tool to identify the ability of human PCSK9 to bind to human LDL R.

  • 重构方法(Reconstitution)

    See Certificate of Analysis for details of reconstitution instruction and specific concentration.

  • 存储(Storage)

    1. Unopened kit should be stored at -25~-15℃ upon receiving.

    2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • 组分(Materials Provided)

    ID
    Components
    Size
    A006-214
    Human LDL R
    160μg
    A007-214
    Biotinylated Human PCSK9
    10μg
    A003-214
    Streptavidin-HRP
    10μg
    PC9-NA003
    Anti-PCSK9 Neutralizing Antibody
    200μg

  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

数据展示

  • 典型数据-Typical Data

    Please refer to DS document for the assay protocol.

     PCSK9 TYPICAL DATA

    INHIBITION OF PCSK9 [BIOTINYLATED]: LDL R BINDING BY ANTI-PCSK9 NEUTRALIZING ANTIBODY
    Serial dilutions of anti-PCSK9 neutralizing antibody (Catalog # PC9-NA003) (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

用户评价
发表评论

前沿进展

 
药物研发进展
  • 英文全称:

    Proprotein convertase subtilisin kexin type 9

  • 中文全称:

    前蛋白转化酶枯草杆菌蛋白酶Kexin-9

  • 种类:

  • 上市药物数量:

    6 详情

  • 临床药物数量:

    28 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
  • 产品基础信息
  • 产品详情
  • 数据展示
  • 用户评价